Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam

Clinical Drug Investigation

Volumn 25, Issue 5, 2005, Pages 307-313

  Del Carmen Carrasco Portugal, Miriam ^a,b   Aguilar Carrasco, José Carlos ^b   Luján, Miguel ^c   Reyes García, Gerardo ^b   Medina Santillán, Roberto ^b   Flores Murrieta, Francisco J ^a,b,d  

^a SECRETARÍA DE SALUD   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c HOSPITAL ESPAÑOL DE MÉXICO   (Mexico)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ETHNIC DIFFERENCE; GERMANY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; INDIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; TIME TO REACH MAXIMUM PLASMA CONCENTRATION;

EID: 20444393432     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525050-00003     Document Type: Article

References (30)

1. Fleischmann R, Iqbal I, Slobodin G. Meloxicam. Expert Opin Pharmacother 2002; 3: 1501-12
2. Ogino K, Hatanaka K, Kawamura M, et al. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997; 55: 44-53
3. Pairet M, van Ryn J, Schierok H, et al. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 1998; 47: 270-6
4. Schmid J, Busch U, Heinzel G, et al. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23: 1206-13
5. Ludwig E, Schmid J, Beschke K, et al. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther 1999; 290: 1-8
6. Burgos-Vargas R, Foeldvari I, Thon A, et al. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2004; 44: 866-72
7. Xu HY, Zhong DF, Zhao LM, et al. Pharmacokinetics of meloxicam in healthy Chinese volunteers. Yao Xue Xue Bao 2001; 36:71-3
8. Castañeda-Hernández G, Hoyo-Vadillo C, Palma-Aguirre JA, et al. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993; 33: 140-5
9. Castañeda-Hernández G, Palma-Aguirre JA, Montoya-Cabrera MA, et al. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996; 41: 433-4
10. Palma-Aguirre JA, González-Llaven J, Flores-Murrieta FJ, et al. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997; 37: 630-4
11. Chávez-Teyes L, Castañeda-Hernández G, Flores-Murrieta FJ. Pharmacokinetics of midazolam in Mexicans: evidence for interethnic variability. Clin Drug Invest 1999; 17: 233-9
12. Flores-Murrieta FJ, Castañeda-Hernández G, Granados-Soto V, et al. Increased bioavailability of sildenafil in Mexican men. JAMA 2000; 283: 1825-6
13. Boudinot PD, Ibrahim SS. High-performance liquid chromatographic assay for piroxicam in human plasma. J Chromatogr 1988; 430: 424-8
14. Avgerinos A, Axarlis S, Dragtsis J, et al. Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5′-hydroxypiroxicam in human plasma and urine. J Chromatogr 1995; 673: 142-6
15. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 3rd ed. Philadelphia (PA): Lea & Febiger, 1995
16. Turck D, Busch U, Heinzel G, et al. Clinical pharmacokinetics of meloxicam. Arzneimittel Forschung 1997; 47: 253-8
17. Busch U, Heinzel G, Narjes H, et al. Interaction of meloxicam with cimetidine, Maalox, or aspirin. J Clin Pharmacol 1996; 36: 79-84
18. Turck D, Schwarz A, Hoffler D, et al. Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. Eur J Clin Pharmacol 1996; 51: 309-13
19. Dasandi B, Shivaprakash M, Saroj H, et al. LC determination and pharmacokinetics of meloxicam. J Pharm Biomed Anal 2002; 28: 999-1004
20. Mobic (meloxicam). Data on file Boehringer Ingelheim International GmbH, 2003
21. Xie HG, Kim RB, Wood AJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50
22. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913-58
23. Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-8
24. Topic E, Stefanovic M, Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin Chem Lab Med 2004; 42: 72-8
25. Schwarz UI. Clinical relevance of genetic polymorphism in the human CYP2C9 gene. Eur J Clin Invest 2003; 33 Suppl. 2: 23-30
26. Dorado P, Beerecz R, Norberto MJ, et al. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003; 59: 221-5
27. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13: 595-606
28. Vidal-Garate J, Castañeda-Hernández G, Hoyo-Vadillo C, et al. Clinical and pharmacokinetic comparison of 2 oral preparations of nifedipine: 10 mg capsules and 20 mg delayed-release tablets. Arch Inst Cardiol Mex 1989; 59: 73-80
29. Panara MR, Renda G, Sciulli MG, et al. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther 1999; 290: 276-80
30. Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35 Suppl. 1: 61-67